1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Abcentra: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Focused Orticumab Research for Treating Inflammation in Coronary Arteries Orticumab, Placebo - Acute Coronary Syndromes, Coronary Arterial Disease (CAD) | Phase 2 | Recruiting | Abcentra | 240 | 2025-08-11 | 2026-01-27 |
| A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Orticumab, Placebo - Psoriasis, Inflammation | Phase 2 | Completed | Abcentra | 77 | 2021-06-30 | 2026-05-11 |
Inflammation (2) · Acute Coronary Syndrome (1) · Coronary Artery Disease (1) · Heart Diseases (1) · Metabolic Syndrome (1) · Myocardial Infarction (1) · Psoriasis (1)
MLDL1278A (2)
United States (2) · Czechia (1) · Hungary (1) · Italy (1) · Poland (1) · Romania (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Joel Neutel, MD (1)